Back

Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates

Uraki, R.; Iida, S.; Halfmann, P. J.; Yamayoshi, S.; Hirata, Y.; Iwatsuki-Horimoto, K.; Kiso, M.; Ito, M.; Furusawa, Y.; Ueki, H.; Sakai-Tagawa, Y.; Kuroda, M.; Maemura, T.; Kim, T.; Mine, S.; Kinoshita-Iwamoto, N.; Li, R.; Liu, Y.; Larson, D.; Fukushi, S.; Watanabe, S.; Maeda, K.; Wang, Z.; Ohmagari, N.; Theiler, J.; Fischer, W.; Korber, B.; Imai, M.; Suzuki, T.; Kawaoka, Y.

2022-08-26 microbiology
10.1101/2022.08.26.505450 bioRxiv
Show abstract

The prevalence of the Omicron subvariant BA.2.75 is rapidly increasing in India and Nepal. In addition, BA.2.75 has been detected in at least 34 other countries and is spreading globally. However, the virological features of BA.2.75 are largely unknown. Here, we evaluated the replicative ability and pathogenicity of BA.2.75 clinical isolates in Syrian hamsters. Although we found no substantial differences in weight change among hamsters infected with BA.2, BA.5, or BA.2.75, the replicative ability of BA.2.75 in the lungs was higher than that of BA.2 and BA.5. Of note, BA.2.75 caused focal viral pneumonia in hamsters, characterized by patchy inflammation interspersed in alveolar regions, which was not observed in BA.5-infected hamsters. Moreover, in competition assays, BA.2.75 replicated better than BA.5 in the lungs of hamsters. These results suggest that BA.2.75 can cause more severe respiratory disease than BA.5 and BA.2 and should be closely monitored.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.